| Renal Cell Carcinoma
Sutent vs Yervoy
Side-by-side clinical, coverage, and cost comparison for renal cell carcinoma.Deep comparison between: Sutent vs Yervoy with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsYervoy has a higher rate of injection site reactions vs Sutent based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Yervoy but not Sutent, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Sutent
Yervoy
At A Glance
Oral
Daily
Multi-targeted RTK inhibitor
IV infusion
Every 3 weeks (monotherapy) or every 6 weeks (combination)
CTLA-4 antagonist
Indications
- Gastrointestinal Stromal Tumors
- Renal Cell Carcinoma
- Well Differentiated Pancreatic Endocrine Neoplasm
- melanoma
- Renal Cell Carcinoma
- Colorectal Carcinoma
- Liver carcinoma
- Non-Small Cell Lung Carcinoma
- Malignant Pleural Mesothelioma
- Squamous cell carcinoma of esophagus
Dosing
Gastrointestinal Stromal Tumors, Renal Cell Carcinoma 50 mg orally once daily on Schedule 4/2 (4 weeks on, 2 weeks off); adjuvant RCC limited to a maximum of nine 6-week cycles.
Well Differentiated Pancreatic Endocrine Neoplasm 37.5 mg orally once daily until disease progression or unacceptable toxicity.
Melanoma (unresectable or metastatic) 3 mg/kg IV every 3 weeks for 4 doses, or 3 mg/kg IV with nivolumab 1 mg/kg IV every 3 weeks for 4 doses followed by nivolumab monotherapy
Melanoma (adjuvant) 3 mg/kg IV every 3 weeks for 4 doses, then 3 mg/kg every 12 weeks for up to 4 additional doses
Renal Cell Carcinoma 1 mg/kg IV with nivolumab 3 mg/kg IV every 3 weeks for 4 doses, followed by nivolumab monotherapy
Colorectal Carcinoma 1 mg/kg IV with nivolumab 240 mg or 3 mg/kg IV (weight-based) every 3 weeks for 4 doses, followed by nivolumab monotherapy
Liver carcinoma 3 mg/kg IV with nivolumab 1 mg/kg IV every 3 weeks for up to 4 doses, followed by nivolumab monotherapy
Non-Small Cell Lung Carcinoma 1 mg/kg IV every 6 weeks with nivolumab 360 mg every 3 weeks, or with nivolumab and 2 cycles of platinum-doublet chemotherapy
Malignant Pleural Mesothelioma 1 mg/kg IV every 6 weeks with nivolumab 360 mg every 3 weeks
Squamous cell carcinoma of esophagus 1 mg/kg IV every 6 weeks with nivolumab 3 mg/kg every 2 weeks or 360 mg every 3 weeks
Contraindications
—
—
Adverse Reactions
Most common (>=25%) Fatigue/asthenia, diarrhea, mucositis/stomatitis, nausea, decreased appetite/anorexia, vomiting, abdominal pain, hand-foot syndrome, hypertension, bleeding events, dysgeusia/altered taste, dyspepsia, thrombocytopenia.
Serious Hepatotoxicity, cardiovascular events, QT interval prolongation and Torsade de Pointes, hemorrhagic events, tumor lysis syndrome, thrombotic microangiopathy, proteinuria, dermatologic toxicities, reversible posterior leukoencephalopathy syndrome, thyroid dysfunction, hypoglycemia, osteonecrosis of the jaw, impaired wound healing.
Postmarketing Hemorrhage associated with thrombocytopenia, esophagitis, acalculous cholecystitis, hypersensitivity reactions including angioedema, serious infection, fistula formation, myopathy/rhabdomyolysis, renal impairment/failure, pulmonary embolism, pleural effusion, pyoderma gangrenosum, arterial aneurysms/dissections/rupture, arterial thromboembolic events.
Most common (>=20%) fatigue, diarrhea, rash, pruritus, nausea, pyrexia, musculoskeletal pain, decreased appetite, cough, headache, dyspnea, vomiting, abdominal pain, arthralgia
Serious immune-mediated colitis, hepatitis, pneumonitis, endocrinopathies, nephritis, dermatologic reactions, neurological toxicities, myocarditis, adrenal insufficiency, hypophysitis, hyperthyroidism, hypothyroidism
Pharmacology
Sunitinib is a small-molecule inhibitor of multiple receptor tyrosine kinases (RTKs) including PDGFRalpha/beta, VEGFR1/2/3, KIT, FLT3, CSF-1R, and RET, which are implicated in tumor growth, pathologic angiogenesis, and metastatic progression of cancer.
Ipilimumab blocks CTLA-4, a negative regulator of T-cell activity, thereby augmenting T-cell activation and proliferation including tumor-infiltrating T-effector cells and reducing T-regulatory cell function.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Sutent
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (11/12)
Yervoy
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Sutent
- Covered on 4 commercial plans
- PA (8/8) · Step Therapy (0/8) · Qty limit (4/8)
Yervoy
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Sutent
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (2/3) · Qty limit (2/3)
Yervoy
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$0/fillfill
Sutent Co-Pay Savings ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Yervoy.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
SutentView full Sutent profile
YervoyView full Yervoy profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.